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Abstract
Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly
used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During
infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because
homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous
system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2
viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate
viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-
Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and
have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade
during the current corona virus pandemic.
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Background
In the era of extremely aging society, hypertension is a
highly prevalent chronic condition in the elderly that will
overlap with many acute conditions such as infection,
surgery, trauma or intoxication. Infection is an unavoid-
able clinical problem in the elderly patient taking antihy-
pertensive medications. Pneumonia and influenza could
be fatal in the elderly patients with cardiovascular com-
plications, which are the result of long-term hyperten-
sion and other risk factors. In fact, vaccination against
pneumonia and influenza is highly recommended in eld-
erly with or without cardiovascular complications. Re-
cent pandemic outbreak of Severe Acute Respiratory
Syndrome corona virus 2 (SARS-CoV-2), so called, cor-
onavirus disease 2019 (COVID-19) are posing a similar
challenge in which the majority of fatalities are being ob-
served in the elderly with hypertension, diabetes and/or
their complications.
Antihypertensive drug therapy may have an impact on
the clinical practice according to the wide variety of pa-
tient conditions. It will vary from mild conditions such
as poor oral intake, volume depletion, orthostatic
hypotension to severe conditions such as sepsis, septic
shock, myocardial damage, overt hear failure, acute kid-
ney injury, and/or multiple organ failure.
The changes in antihypertensive drug therapy should
be based on weighing the risk benefit ratio. But there are
few specific recommendations to guide the use of anti-
hypertensive drugs in terms of vulnerability to specific
infection, septic shock, and/or organ failure.
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General aspects of infection and hypertension
management
There are some general aspects in relation to hyperten-
sion management or antihypertensive drug use when
some infection is impending or ongoing. First of all, be-
cause hypertension is basically dependent on the sodium
balance, when sodium or food intake is stopped, there
could be an increased risk for unexpected blood pressure
decrease and hypotension. Negative sodium balance can
be exacerbated by febrile condition and the use of potent
diuretics. In this situation, increase in renin-angiotensin-
aldosterone system (RAS) activation and sympathetic
nervous system acts as a compensatory mechanism to
mitigate hypotension. As such, the patient taking potent
or long acting RAS blockade or beta blocker might be
vulnerable to hemodynamic instability compared to cal-
cium antagonist. For this issue, diuretics does not have
blocking effect of compensatory system but it could ex-
acerbate underlying sodium depleting situation. These
theoretical speculations might be one of possible explan-
ation for the reason why calcium antagonist have super-
ior profile in term of inter-individual visit to visit blood
pressure variabilities. But, despite of all these specula-
tions, there is few studies to answer this questions and
clinical practice when a patient has asymptomatic
hypotension or orthostatic hypotension is solely
dependent on the physician’s discretions. Because RAS
blockade or beta blocker is recommended for the patient
with cardiovascular complications, stopping these drugs
may be harmful. In a recent retrospective population
based cohort study, Hsu W, et al., reported that estab-
lished RAS blockade therapy before sepsis will be pro-
tective for the sepsis related mortality [1]. These results
seems to be in line with the recent study showing de-
pressed sympathetic modulation can be a signal for sep-
sis in patient with infection [2]. Some mediators to
suppress sympathetic nervous system may be required
for sustained hypotension so that those mediators may
not be effective if additional blocking is not possible due
to already established sympathetic blockade. Similarly, in
retrospective studies for heart failure patients, with-
drawal of RAS blockade or beta blocker were associated
with poor prognosis [3, 4]. As such, there is no evidence
to stop using these drugs in infection patients unless
they are associated with hemodynamic instability. How-
ever, in patients with volume depletion and symptomatic
hypotension, it would be prudent to stop antihyperten-
sive medications and diuretics until blood pressure is
normalized and the volume status is recovered. In pa-
tients who are hemodynamically stable, temporarily
stopping RAS blockade or beta blocker seems to be pos-
sible only when the patient has no hypertension related
complications such as heart failure, coronary artery dis-
ease, and other vascular complications. Even in these
subjects, one should consider the adverse events result-
ing from rebound increase in blood pressure. Moreover,
in the study by Ohkubo et al., including 6105 patients
with a history of stroke and/or transient ischemic attack
(mean age, 64 years), it was reported that perindopril de-
creased pneumonia risk in Asian but not in non-Asian
subjects [5].
Septic shock and antihypertensive drugs
Even with those retrospective studies showing that stop-
ping RAS blockade or beta blocker is associated with
poor prognosis, it is not usual to use vasoconstrictor or
inotropic without temporary withdrawal of RAS block-
ade or beta blocker in a real world clinical practice for
the patient with acute hypotension, acute kidney injury,
or hyperkalemia related to infection [6]. Besides the
toxin supplied by infectious organisms, catecholamine or
stress induced cardiomyopathy, tachycardia induced car-
diomyopathy, and direct invasion of infectious agents
could precipitate hypotension during infection. Acute
hemodynamic instability or hypotension is a serious con-
dition during acute infection which requires stopping or
adjustment of antihypertensive drug dosage according to
the patient’s hemodynamic status.
Pandemic viral diseases
Yearly outbreak of the seasonal flu is a huge burden on
the healthcare system and survival in extremely older pa-
tients or in patients with high risk profiles such as older
age, diabetes, chronic diseases of the heart, kidney, lung,
and liver [7]. Fortunately, there are key available strat-
egies to cope with it, which are specific to the infectious
agent such as anti-viral therapy, vaccination, and other
preventive approaches. Hypertension is prevalent in high
risk flu patients because they are usually older and with
cardiovascular complications. But antihypertensive
agents could be adjusted according to the general and
hemodynamic conditions only after infection begins and
it will be only temporary even when the drugs need ad-
justments. There is no issue about adjustment of antihy-
pertensive drug use to protect from infection
preemptively because there is no direct involvement of
antihypertensive drugs in the infectious process itself.
In contrast to pandemic flu, it is highlighted that
angiotensin converting enzyme 2 (ACE2) of the lung
type 2 alveolar epithelial cell acts as a non-catalytic re-
ceptor for SARS-CoV-1 and presumably for SARS-CoV-
2 to infect the cell [8]. ACE2 is reported to be predomin-
antly localized on endothelial cells. Its mRNA is reported
to be most highly expressed in testis, kidney, and, heart
and also expressed in brain, intestine, and lungs [9].
Thus, there have been growing concerns about hyper-
tension being a risk factor for severe COVID-19 and the
possibility of RAS inhibitors being an aggravating factor
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of severe COVID-19 due to the theoretical increase in
the expression of systemic ACE2 with its use. The pan-
demic of SARS-CoV-2 which began in Wuhan, China
from December 2019, has spread rapidly around the
world. Severe lung damage and high mortality rates have
been reported, particularly in the elderly and those with
comorbidities. In particular, the high prevalence of
hypertension and diabetes suggests that they maybe risk
factors for severe COVID-19. The prevalence of hyper-
tension is apparently high in patients with severe
COVID-19, however, considering the age of those pa-
tients, the actual prevalence of hypertension does not
seem to be higher. Zhou et al. analyzed the clinical char-
acteristics of 191 patients diagnosed in Wuhan. Among
them, the average age of deaths (n = 54) was 69 years,
and the prevalence of hypertension was 48%, which is
quite comparable to the prevalence of hypertension in
the representative population of those ages [10]. Until
now, none of the papers published through multivariate
analysis indicated that hypertension was an independent
risk factor for severe COVID-19. In the study by Guan
et al., reporting the clinical features of 1099 COVID-19
patients diagnosed in Wuhan, the prevalence of hyper-
tension was higher in severe patients (N = 173, mean age
52 years) than in mild patients (mean age 45
years)(23.7% vs. 13.4%), but it was not particularly higher
when considering the prevalence of hypertension in that
age group [11]. Therefore, there is no scientific evidence
to suggest that hypertension itself is an independent risk
factor for severe infection or mortality by COVID-19.
The higher prevalence of hypertension in patients with
COVID-19 is more likely due to the fact that the age of
severe patients was significantly older and because major
complications of hypertension such as chronic heart fail-
ure, cerebral infarction, and chronic renal failure make
the patient much more vulnerable to progression to se-
vere infection or death.
In 2004, since the SARS-CoV-1 outbreak in Asia, the
coronavirus has been shown to use ACE2 proteins in the
epithelial cell membrane in the lung alveoli as a recep-
tor. The viral spike(S) glycoprotein attaches to the ACE2
proteins which have been shown to facilitate viral entry
and in theory, make the patient vulnerable to lower re-
spiratory tract infection or viral pneumonia [12, 13].
Since the COVID-19 outbreak, role of ACE2 in the
pathophysiology of COVID-19 has drawn a lot of inter-
est in the social media world as well as scientific groups
due to the growing concerns that increased expression
of ACE2 may increase the risk for severe COVID-19. In
a recent report, the main receptor of the spike (S) glyco-
protein of SARS-CoV-2 is ACE2 and its affinity has been
reported to be higher than that of SARS-CoV 1 [14]. So
the key point of concern is that RAS inhibitor (ACE in-
hibitor, angiotensin receptor blocker), a drug commonly
used in hypertensive patients, can theoretically raise
ACE2 expression by a classical feedback system in the
biochemical pathway when an enzyme or receptor was
blocked (Fig. 1, a). When ACE2 is activated, Angiotensin
1–7 is increased instead of Angiotensin II. Angiotensin
1–7 is known to have an effect of protecting cardiovas-
cular diseases by binding to the receptor Mas receptor
to promote vasodilation, antioxidant and anti-
inflammatory effects [15]. On the other hand, when it
comes to COVID-19, the possibility exists that ACEI or
ARB can be an exacerbation factor by increasing the ex-
pression of ACE2. As such, there have been increased
incidence where patients or physicians change the anti-
hypertensive medications to other drugs or discontinue
the drugs due to concerns about the concerns, whether
real or not, for increased risk of severe COVID-19. How-
ever, the Korean society of Hypertension would like to
emphasize that currently, there is no scientific basis for
taking such measures. First, there is no epidemiologic evi-
dence for increased severe COVID-19 or mortality in pa-
tients who were taking RAS inhibitors. Second, it is still
unclear whether or not RAS inhibition results in increased
expression of ACE2 in systemic level and/or tissue includ-
ing epithelial cells (Fig. 1). Even though there are reports
that the concentration of ACE2 in the blood rises after ad-
ministration of the first RAS blockade, there are conflict-
ing reports that also suggest otherwise [16, 17]. Third,
since ACE2 is a receptor for SARS-CoV-1 and 2, if RAS
blockade does indeed exacerbates corona virus infection,
obvious increase in mortality and severe infection in pa-
tients receiving RAS inhibitor should have been reported
during the SARS-CoV-1 epidemic. As we all know, this
was obviously not the case. On the contrary, it has been
reported that ACE2 protects against severe acute lung in-
jury. Study by Deshotels et al. have shown that Angioten-
sin II, which is highly activated in severe infection, results
in increased ACE2 internalization and ACE2 degradation
[18]. This has importance implications as the interaction
between ACE2 and SARS-CoV-1 is very complex and the
net expression of ACE2 cannot be predictable in a real pa-
tient (Fig 1, b) [19]. Moreover, in vivo studies have shown
that decreased ACE2 during SARS-CoV-1 infection exac-
erbated acute lung injury. Imai et al. conducted experi-
ments by inducing acute lung injury through gastric acid
aspiration in mice. In ACE knockout mice, acute lung in-
jury was significantly inhibited, whereas in ACE2 knock-
out mice, acute lung injury worsened compared to wild
type. On the other hand, acute lung injury was signifi-
cantly improved by recombinant ACE2 administration,
demonstrating the protective effect of ACE2 in acute lung
injury [20]. In addition, Kuba et al. conducted experiments
with the mice SARS-CoV-1 model. The spike protein of
SARS-CoV-1 attaches to ACE2 and downregulates ACE2
and activates Angiotensin II to exacerbate acute lung
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injury. In contrast, RAS blockade with losartan 15mg/kg
had a protective effect against acute lung injury caused by
SARS-CoV-1 infection (Fig 1, b). Given that COVID-19
has similar pathophysiological mechanisms to SARS-CoV-
1 infection, increase in ACE2 or RAS blockade might even
be protective against severe infection or death.
In summary, 1) the prevalence of hypertension in pa-
tients with severe COVID-19 is high. However, it is
more likely due to the fact that severe patients tend to
be older and commonly have complications of hyperten-
sion, such as heart failure, coronary artery disease, stroke
and CKD. Currently, there is no scientific evidence that
hypertension is an independent risk factor for severe in-
fection or death until proven otherwise. 2) Regarding the
concerns for increased risk of severe infection or death
due to the theoretical concerns that taking RAS inhibi-
tors may increase lung ACE2, there is no clinical evi-
dence to suggest that patients taking RAS inhibitors may
have adverse prognosis during COVID-19. In fact, it is
possible that RAS blockade has protective effect against
severe COVID-19 based on previous reports of their
protective effect in animal models of SARS-CoV-1 infec-
tion. 3) If RAS inhibitors administered due to high blood
pressure or other cardiovascular disease were stopped
abruptly, there is risk for excessive increase in blood
pressure that may precipitate cardiovascular complica-
tions. However, we do acknowledge that the above-
mentioned issues are valid concerns that deserve more
research as quickly as possible. But without any scientific
evidence to suggest otherwise, we the Korean Society of
Hypertension endorse the recent recommendation by
the European Society of Cardiology and recommend 1)
In hemodynamically stable patients who were taking
RAS inhibitors to be maintained on RAS blockade 2) In
hemodynamically stable, treatment naïve patients who
have compelling indication for using RAS inhibitors to
be administered with RAS inhibitors according to the
current guidelines 3) In patients without COVID-19 to
be prescribed with RAS inhibitors if there are clinical in-
dications to do so. 4) In hemodynamically unstable pa-
tients with COVID-19, prudent reduction or withdrawal
of antihypertensive medications can be considered with
consideration for the comorbidities and the indications
for using the drug(s) before the infection.
Conclusions
In conclusion, the use or temporary adjustment of anti-
hypertension drugs during infectious disease could be
individualized according to volume status, hemodynamic
stability, comorbid cardiovascular disease profiles, and
antihypertensive drug class. Also, the use of RAS block-
ade SARS-CoV-2 pandemic before infection should be
maintained based on the current scientific knowledge.
More researches are needed for the use of antihyperten-
sive drugs before and during severe infection or
epidemics.
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